## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: PEG 6.21 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($382.67)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. William Blair initiates Waters stock with Outperform rating, sees BD acquisition synergies**
- Source: Investing.com Nigeria | 20260105T120851 | Bullish | Relevance: 100%
- William Blair initiated coverage on Waters Corp. (NYSE:WAT) with an Outperform rating, citing better-than-expected fit and synergy potential from the BD Biosciences and Diagnostics Solutions portfolio acquisition. The firm projects mid-teens EPS compound annual growth and nearly $22 EPS by 2030 due to the transaction's benefits. This positive outlook follows strong Q3 2025 results for Waters, which exceeded analyst expectations and led to several analyst upgrades and price target increases.

**2. Estimating The Intrinsic Value Of Waters Corporation (NYSE:WAT)**
- Source: Simply Wall Street | 20260104T120834 | Somewhat-Bullish | Relevance: 100%
- This article estimates the intrinsic value of Waters Corporation (NYSE: WAT) using a 2-stage Discounted Cash Flow (DCF) model. The analysis suggests a fair value of US$362 for Waters, indicating its current share price of US$382 is trading at similar levels. The valuation considers future cash flows, a terminal value calculation, and a discount rate of 7.9%.

**3. Waters-Becton Dickinson Agreement Could Yield Greater Returns Than Anticipated, Says Analyst**
- Source: Bitget | 20260106T030820 | Bullish | Relevance: 100%
- William Blair analyst Matt Larew believes the merger between Becton, Dickinson and Company's Biosciences & Diagnostic Solutions division and Waters Corporation will yield greater synergies and returns than initially expected. The firm projects significant earnings per share growth for Waters by 2028 and anticipates the stock could gain about 20% by the end of 2026. This positive outlook is supported by a strong strategic match, improved investor sentiment, and comparison to successful large-scale acquisitions in the life sciences sector.

**4. William Blair inicia cobertura da Waters com recomendação de Outperform**
- Source: Investing.com Brasil - Finanças, Câmbio e Investimentos | 20260105T120856 | Bullish | Relevance: 100%
- William Blair iniciou a cobertura da Waters Corp. (NYSE:WAT) com uma recomendação de Outperform, projetando que a aquisição da BD Biosciences and Diagnostics Solutions impulsionará o lucro por ação para quase US$ 22 até 2030. Esta análise coincide com a Waters reportando resultados financeiros do terceiro trimestre de 2025 acima do esperado e recebendo classificações positivas de outras firmas de análise como Wolfe Research e Morgan Stanley.

**5. William Blair initiates Waters stock with Outperform rating, sees BD acquisition synergies**
- Source: Investing.com | 20260105T120928 | Bullish | Relevance: 95%
- William Blair has initiated coverage on Waters Corp. (NYSE:WAT) with an Outperform rating, highlighting the strategic advantages of its acquisition of BD Biosciences and Diagnostics Solutions. The firm believes this acquisition will generate significant synergies, leading to a mid-teens EPS compound annual growth rate and potentially $22 EPS by 2030. This positive outlook is further supported by Waters' strong financial health, as evidenced by its Q3 2025 results and several other analyst upgrades.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | William Blair | $0 | $0 | 0% |
| 2025-12-15 | Wells Fargo | $415 | $385 | +8% |
| 2025-12-10 | Wolfe Research | $480 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | William Blair | init | Outperform |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-10 | Wolfe Research | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Valuation stretched: PEG 6.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 6.21 signals overvaluation risk, limited margin of safety. Forward P/E 28.0x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Analyst sentiment positive (1 raises, avg +8%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.9B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.21 |
| Forward P/E | 28.0 |
| Current P/E | 30.5 |
| YoY Growth | 9.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.2% to 3.2% (+3.0% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 73rd percentile. MRS_5 at 2.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.67), confirming momentum. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.21% (CS: 74) | Strong |
| RSI_14 | 64.9 | Neutral |
| MACD Histogram | 0.67 | Bullish |
| vs SMA20 | 1.039x | Above |
| vs SMA50 | 1.051x | Above |
| vs SMA200 | 1.179x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $400.51
- **Stop Loss:** $382.67 (4.5% risk)
- **Target:** $418.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 73
- **Position Value:** $29,237.23
- **Portfolio %:** 29.24%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*